268 related articles for article (PubMed ID: 24882574)
1. Targeting the oncogenic Met receptor by antibodies and gene therapy.
Vigna E; Comoglio PM
Oncogene; 2015 Apr; 34(15):1883-9. PubMed ID: 24882574
[TBL] [Abstract][Full Text] [Related]
2. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.
Michaud NR; Jani JP; Hillerman S; Tsaparikos KE; Barbacci-Tobin EG; Knauth E; Putz H; Campbell M; Karam GA; Chrunyk B; Gebhard DF; Green LL; Xu JJ; Dunn MC; Coskran TM; Lapointe JM; Cohen BD; Coleman KG; Bedian V; Vincent P; Kajiji S; Steyn SJ; Borzillo GV; Los G
MAbs; 2012; 4(6):710-23. PubMed ID: 23007574
[TBL] [Abstract][Full Text] [Related]
4. NK4 gene therapy targeting HGF-Met and angiogenesis.
Matsumoto K; Nakamura T
Front Biosci; 2008 Jan; 13():1943-51. PubMed ID: 17981681
[TBL] [Abstract][Full Text] [Related]
5. Targeting MET in cancer: rationale and progress.
Gherardi E; Birchmeier W; Birchmeier C; Vande Woude G
Nat Rev Cancer; 2012 Jan; 12(2):89-103. PubMed ID: 22270953
[TBL] [Abstract][Full Text] [Related]
6. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
[TBL] [Abstract][Full Text] [Related]
7. [MET receptor inhibition: Hope against resistance to targeted therapies?].
Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
[TBL] [Abstract][Full Text] [Related]
8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
Chiara F; Michieli P; Pugliese L; Comoglio PM
J Biol Chem; 2003 Aug; 278(31):29352-8. PubMed ID: 12746450
[TBL] [Abstract][Full Text] [Related]
10. [Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
Li Y; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):625-34. PubMed ID: 25130970
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
12. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
Jarantow SW; Bushey BS; Pardinas JR; Boakye K; Lacy ER; Sanders R; Sepulveda MA; Moores SL; Chiu ML
J Biol Chem; 2015 Oct; 290(41):24689-704. PubMed ID: 26260789
[TBL] [Abstract][Full Text] [Related]
13. Biological significance and targeting of c-Met tyrosine kinase receptor in cancer.
Goetsch L; Caussanel V; Corvaia N
Front Biosci (Landmark Ed); 2013 Jan; 18(2):454-73. PubMed ID: 23276936
[TBL] [Abstract][Full Text] [Related]
14. The current state of molecularly targeted drugs targeting HGF/Met.
Yano S; Nakagawa T
Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
[TBL] [Abstract][Full Text] [Related]
16. Gene of the month: MET.
Skead G; Govender D
J Clin Pathol; 2015 Jun; 68(6):405-9. PubMed ID: 25987653
[TBL] [Abstract][Full Text] [Related]
17. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
Sattler M; Salgia R
Curr Oncol Rep; 2007 Mar; 9(2):102-8. PubMed ID: 17288874
[TBL] [Abstract][Full Text] [Related]
18. A receptor-antibody hybrid hampering MET-driven metastatic spread.
Modica C; Basilico C; Chiriaco C; Borrelli N; Comoglio PM; Vigna E
J Exp Clin Cancer Res; 2021 Jan; 40(1):32. PubMed ID: 33446252
[TBL] [Abstract][Full Text] [Related]
19. MET Oncogene Targeting for Cancer Immunotherapy.
Lombardi AM; Sangiolo D; Vigna E
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892318
[TBL] [Abstract][Full Text] [Related]
20. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
